- Home
- NAUT vs ENTX Comparison
NAUT vs ENTX Comparison
Compare NAUT & ENTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NAUT
- ENTX
- Stock Information
- Founded
- NAUT 2016
- ENTX 2010
- Country
- NAUT United States
- ENTX Israel
- Employees
- NAUT N/A
- ENTX N/A
- Industry
- NAUT Biotechnology: Laboratory Analytical Instruments
- ENTX Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- NAUT Industrials
- ENTX Health Care
- Exchange
- NAUT Nasdaq
- ENTX Nasdaq
- Market Cap
- NAUT 91.5M
- ENTX 104.0M
- IPO Year
- NAUT N/A
- ENTX 2018
- Fundamental
- Price
- NAUT $0.71
- ENTX $1.98
- Analyst Decision
- NAUT Hold
- ENTX Strong Buy
- Analyst Count
- NAUT 2
- ENTX 1
- Target Price
- NAUT $3.88
- ENTX $10.00
- AVG Volume (30 Days)
- NAUT 207.1K
- ENTX 43.1K
- Earning Date
- NAUT 07-29-2025
- ENTX 08-08-2025
- Dividend Yield
- NAUT N/A
- ENTX N/A
- EPS Growth
- NAUT N/A
- ENTX N/A
- EPS
- NAUT N/A
- ENTX N/A
- Revenue
- NAUT N/A
- ENTX $223,000.00
- Revenue This Year
- NAUT N/A
- ENTX N/A
- Revenue Next Year
- NAUT N/A
- ENTX N/A
- P/E Ratio
- NAUT N/A
- ENTX N/A
- Revenue Growth
- NAUT N/A
- ENTX N/A
- 52 Week Low
- NAUT $0.66
- ENTX $1.41
- 52 Week High
- NAUT $3.09
- ENTX $2.79
- Technical
- Relative Strength Index (RSI)
- NAUT 44.72
- ENTX 48.00
- Support Level
- NAUT $0.68
- ENTX $1.87
- Resistance Level
- NAUT $0.75
- ENTX $2.18
- Average True Range (ATR)
- NAUT 0.05
- ENTX 0.18
- MACD
- NAUT -0.00
- ENTX -0.00
- Stochastic Oscillator
- NAUT 29.50
- ENTX 31.82
About NAUT Nautilus Biotechnolgy Inc.
Nautilus Biotechnology Inc is a development stage life sciences company creating a platform technology for quantifying and unlocking the complexity of the human proteome. The Company transform the field of proteomics by democratizing access to the proteome and enabling fundamental advancements across human health and medicine. Company's products includes: Proteome Analysis System, Reagent Kits, Software and analysis.
About ENTX Entera Bio Ltd.
Entera Bio Ltd is a clinical-stage biopharmaceutical company engaged in the development of orally delivered macromolecule therapeutics, including peptides and therapeutic proteins. The company focuses on underserved, chronic medical conditions where oral administration of a mini tablet peptide or peptide replacement therapy has the potential to significantly shift a treatment paradigm. Its product candidates are; EB613 for the treatment of osteoporosis and EB612 for the treatment of hypoparathyroidism are first-in-class mini tablet formulations of synthetic human PTH (1-34) (teriparatide), designed to have differing pharmacokinetic, or PK, profiles.